A blood test for colon cancer screening coming soo
The first blood test to screen for colorectal cancer could be approved this year, a breakthrough that could drastically increase the number of people diagnosed with the second-highest cause of cancer death in the United States.
The test, developed by Guardant Health, would not replace colonoscopy but offers a less invasive and more palatable way to detect colon cancer. It is 83% effective in finding colorectal cancers, offering hope for improved detection rates.
Experts are excited about the potential of a blood-based test for colon cancer, as colonoscopy is currently the most accurate way to detect colon and rectal cancers. However, less than 60% of eligible people are up to date on colon cancer screenings, with factors like the “ick” factor and logistical barriers deterring many from getting colonoscopies.
The Guardant blood test works by detecting DNA released by cancerous tumors in the blood. A positive test would require a follow-up colonoscopy for diagnosis and treatment planning, although the test is less effective in finding early-stage polyps.
The test is expected to receive FDA approval this year, with recommended testing every three years starting at age 45. This new screening option could potentially save lives by increasing detection rates and encouraging more people to get screened for colorectal cancer.
Overall, the approval of the blood test for colorectal cancer represents a major advancement in cancer screening technology, offering a more accessible and potentially life-saving option for those at risk of this preventable disease.
